Areterna
Areterna is a US-based subsidiary of Synthgene Biotechnology that supplies mRNA and oligonucleotide raw materials — cap analogs, nucleotides, enzymes, LNPs, and IVT kits — alongside services such as antibody-LNP conjugation and veterinary vaccine development, serving pharma, biotech, and CDMO customers globally.
- Company typePrivate
- Founded2023
- HeadquartersGaithersburg, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Areterna does
Areterna LLC is a US-based biotechnology company founded in 2023 as a wholly owned subsidiary of Synthgene Biotechnology Co., Ltd (founded 2018 in China), serving as the commercial arm for mRNA and oligonucleotide raw materials in the US and European markets. The company supplies a broad portfolio of reagents and consumables used in mRNA synthesis and oligonucleotide manufacturing — including cap analogs (with proprietary license-free IP including the CAP5/ENE generation), standard and modified nucleotides (50+ variants), engineered enzymes such as low-dsRNA T7 RNA polymerase, proprietary ionizable lipids (LNP007, LNP009, LNP016), IVT and capping kits, ELISA-based impurity detection kits, tool mRNAs, phosphoramidites, nucleosides, and dNTP/ddNTP lines for molecular diagnostics. Areterna also offers services spanning analytical development, LNP screening, IVT process development, custom oligo synthesis, antibody-LNP conjugation for in vivo CAR-T applications (HiSynth platform), and an end-to-end veterinary mRNA vaccine development service with BSL-3 capability priced at approximately $0.50 per dose. The business model is primarily unit-based product sales (RUO and GMP grades) supplemented by professional services and channel distribution through BIORON GmbH (Germany), Medsol (Egypt), and Bion2 (Czechia), with a co-development partnership with Biomay AG extending reach into European and North American mRNA CDMOs. Customer segments include pharma and biotech companies developing mRNA therapeutics and vaccines, mRNA CDMOs, cell therapy developers working on in vivo CAR-T, and veterinary vaccine companies.
Areterna firmographics
Firmographics- Name
- Areterna
- Legal name
- Areterna LLC
- Website
- https://areterna.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Areterna is a US-based subsidiary of Synthgene Biotechnology that supplies mRNA and oligonucleotide raw materials — cap analogs, nucleotides, enzymes, LNPs, and IVT kits — alongside services such as antibody-LNP conjugation and veterinary vaccine development, serving pharma, biotech, and CDMO customers globally.
- Ownership category
- akta.pro rank
Areterna industry classification
Industry- Product category
- mRNA Manufacturing Raw Materials
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)
- akta.pro secondary industries
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where Areterna is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Areterna business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- mRNA Raw Materials Sales: Sale of cap analogs, nucleotides, modified nucleotides, enzymes, LNP products, and IVT kits for mRNA synthesis and manufacturing. Products available in RUO and GMP grades.
- Oligonucleotide Raw Materials Sales: Sale of phosphoramidites for solid-phase DNA and RNA synthesis supporting cGMP oligo manufacturing.
- GMP-Grade Product Sales: GMP-grade raw materials including cap analogs, NTPs, and modified NTPs for clinical trials and commercial manufacturing. Drug Master Files filed with FDA.
- Veterinary mRNA Vaccine Development Services: End-to-end service for animal mRNA vaccine development including sequence design, mRNA synthesis, LNP formulation, analytical testing, and pre-clinical testing.
- Antibody-LNP Conjugation Services: Conjugation and encapsulation services for antibody-LNP formulations enabling in vivo CAR-T research.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | Veterinary mRNA vaccine candidates |
| Unit Pricing | Pay-as-you-go | Cap Analogs Product Line |
| Unit Pricing | Multi-year contract | GMP Grade Products |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
Areterna product offering
Product offeringCore offering
Areterna manufactures and sells raw materials and reagents used by pharma and biotech companies to build mRNA and oligonucleotide-based medicines, including cap analogs, standard and modified nucleotides, enzymes, ionizable lipids and LNP screening products, IVT and capping kits, impurity detection kits, tool mRNAs, and a full range of phosphoramidites and nucleosides. The catalog is offered in both RUO and GMP grades, with selected cap analogs covered by Drug Master Files filed with the FDA. In parallel, Areterna delivers professional services spanning animal mRNA vaccine development, antibody-LNP conjugation for in vivo CAR-T, LNP screening, IVT process development, analytical method development, and custom oligonucleotide synthesis.
Product overview
Areterna is a biotechnology company providing mRNA and oligonucleotide raw materials, reagents, and services for therapeutic development. The product portfolio includes four major categories: (1) mRNA Raw Materials - covering cap analogs, nucleotides, modified nucleotides, enzymes, LNP products, IVT kits, detection kits, tool mRNAs, and CAR-T related products; (2) Phosphoramidites - DNA and RNA phosphoramidite building blocks including DNA, 2'-O-TBDMS, 2'-O-Me, 2'-O-MOE, 2'-Fluoro, and 2'-O-Propargyl variants; (3) Nucleosides - modified and protected nucleosides for oligonucleotide synthesis; and (4) Molecular Diagnostics - dNTPs, dNMPs/dNDPs, and ddNTPs for PCR, sequencing, and diagnostics. The company also offers services including animal mRNA vaccine development, analytical development, LNP screening, IVT process development, and custom oligo synthesis. All products are backed by ISO9001-certified quality systems, with GMP-grade materials available for clinical trials and Drug Master Files filed with FDA.
Differentiator
Problem solved
Functional benefit
Brands
- HiSynth: HiSynth antibody-LNP conjugation technology platform for in vivo CAR-T therapy
Products and services
- Cap Analogs
Quantifiable outcome
- CAP5 (ENE) provides superior antigenicity against VZV with stronger gE-specific IgG antibody responses and higher VZV-specific IFNγ levels compared to benchmark m7GpppAmG in mice
- +3 more outcomes
Companies that use Areterna
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Areterna technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Areterna partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Bion2coreDistribution agreement for Eastern Europe signed between Synthgene Bio, BIORON, and Bion2. Represents a major step toward global expansion, enhancing access to key resources for mRNA and oligo research and manufacturing in Eastern Europe.
- Biomay AGcoreStrategic partnership to jointly serve mRNA CDMO customers in Europe and North America. Collaboration expands Areterna's reach in Europe and strengthens Biomay's mRNA CDMO offerings with low-cost GMP raw materials from Areterna.
- BIORON GmbHcoreGlobal distribution agreement with BIORON GmbH, a premium manufacturer and distributor based in Römerberg, Germany. BIORON distributes Areterna's mRNA and oligonucleotide raw materials globally, providing custom clearance and local language support.
- Medsol CorporationcoreGlobal distribution agreement with Medsol Corporation, a distributor based in Cairo, Egypt. Medsol provides distribution services for Areterna's raw materials and services in the Middle East region.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Areterna competitors and assessment
Company assessmentDirect peers
- ChemGenes: ChemGenes manufactures phosphoramidites, nucleosides, and other nucleic acid synthesis building blocks for DNA, RNA, and oligonucleotide production. It directly competes with Areterna's phosphoramidite and nucleoside lines.
- Jena Bioscience: Jena Bioscience supplies nucleotides, modified nucleotides, cap analogs, and reagents for mRNA synthesis and oligonucleotide chemistry. Its product portfolio directly overlaps with Areterna's nucleotide, cap analog, and reagent catalog.
- Hongene Biotech: Hongene Biotech produces modified nucleotides, phosphoramidites, and nucleic acid synthesis reagents, with GMP capabilities. It is a direct competitor to Areterna across the modified nucleotide and oligo raw material portfolio.
- BioSynth: BioSynth manufactures nucleotides, enzyme substrates, and carbohydrate/peptide chemistry for research and diagnostic applications. Its nucleotide and reagent lines overlap with Areterna's mRNA and oligo raw material offerings.
- TriLink BioTechnologies: TriLink is a leading manufacturer of mRNA capping reagents (notably the patented CleanCap cap analog), modified nucleotides, and GMP-grade mRNA raw materials for therapeutic developers. It is the closest direct competitor to Areterna's cap analog and mRNA raw material portfolio.
Broad incumbents
- Agilent Technologies: Agilent supplies phosphoramidites, reagents, and instruments for oligonucleotide synthesis and molecular diagnostics through its diagnostics and genomics group. Its phosphoramidite and dNTP lines partially overlap with Areterna's portfolio.
- Cytiva: Cytiva (formerly part of GE Life Sciences) provides nucleic acid synthesis reagents, oligonucleotides, and bioprocessing products. Its oligo synthesis and nucleic acid chemistry lines overlap with Areterna's phosphoramidite and reagent offerings.
- Merck KGaA / Sigma-Aldrich (Life Science): Merck's Life Science business supplies a deep catalog of nucleotides, modified nucleotides, enzymes, and lipids for mRNA and oligonucleotide synthesis, including GMP-grade offerings. It is a broad incumbent competitor to Areterna's reagent portfolio.
- Thermo Fisher Scientific: Thermo Fisher operates a large life sciences tools portfolio including nucleic acid reagents, mRNA synthesis materials, GMP manufacturing services, and CDMO capabilities through Patheon. It competes broadly with Areterna across reagents and services but at far larger scale.
Emerging players
- Bioneer: Bioneer manufactures nucleotides, oligo synthesis reagents, and molecular biology enzymes, with growing GMP and mRNA-related offerings. It is an emerging peer intersecting with Areterna's nucleotide, enzyme, and oligo reagent lines.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Areterna social profiles
Digital presenceAreterna compliance and trust
Trust signalCompliance2 records
Areterna financial estimates
Financial estimateRevenue estimate
Valuation estimate
Areterna leadership team
Management profileNumber of profiles
Areterna funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Areterna M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Areterna
What does Areterna do?
Areterna manufactures and sells raw materials and reagents used by pharma and biotech companies to build mRNA and oligonucleotide-based medicines, including cap analogs, standard and modified nucleotides, enzymes, ionizable lipids and LNP screening products, IVT and capping kits, impurity detection kits, tool mRNAs, and a full range of phosphoramidites and nucleosides. The catalog is offered in both RUO and GMP grades, with selected cap analogs covered by Drug Master Files filed with the FDA. In parallel, Areterna delivers professional services spanning animal mRNA vaccine development, antibody-LNP conjugation for in vivo CAR-T, LNP screening, IVT process development, analytical method development, and custom oligonucleotide synthesis.
Is Areterna a public or private company?
Areterna is a private company. It is classified as corporate owned and is currently operating.
When was Areterna founded?
Areterna was founded in 2023. It employs 101 to 250 people.
Where is Areterna based?
Areterna is headquartered in Gaithersburg, United States, in the North America region.
How does Areterna make money?
Five revenue lines are on record. mRNA Raw Materials Sales are the primary driver. The others are oligonucleotide Raw Materials Sales, GMP-Grade Product Sales, veterinary mRNA Vaccine Development Services and antibody-LNP Conjugation Services.
Who are Areterna's main competitors?
Direct peers on record are ChemGenes, Jena Bioscience, Hongene Biotech, BioSynth and TriLink BioTechnologies. Broad incumbents are Agilent Technologies, Cytiva, Merck KGaA / Sigma-Aldrich (Life Science) and Thermo Fisher Scientific. Bioneer is listed as an emerging player.
Does Areterna have an API?
No public API is recorded for Areterna.
What industry is Areterna in?
Areterna's product category is mRNA Manufacturing Raw Materials. Its primary akta.pro industry code is HLAAADAF, RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 3254 and its SIC code is 2833.